BDBM622524 US20230312583, Compound VI-1

SMILES COc1cc(Nc2ncc3ccc4nc(C)n(C(C)C)c4c3n2)ncc1N1CCOCC1

InChI Key InChIKey=UYDMDSBIXKYMQD-UHFFFAOYSA-N

Data  7 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 7 hits for monomerid = 622524   

TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622524(US20230312583, Compound VI-1)
Affinity DataIC50:  1.55nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622524(US20230312583, Compound VI-1)
Affinity DataIC50:  1.5nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMast/stem cell growth factor receptor Kit(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622524(US20230312583, Compound VI-1)
Affinity DataIC50:  46nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622524(US20230312583, Compound VI-1)
Affinity DataIC50:  388nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622524(US20230312583, Compound VI-1)
Affinity DataIC50:  89.1nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622524(US20230312583, Compound VI-1)
Affinity DataIC50:  245nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622524(US20230312583, Compound VI-1)
Affinity DataIC50:  397nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent